NEXT GENERATION SEQUENCING BASED UBTF TANDEM DUPLICATION MEASURABLE RESIDUAL DISEASE (UBTF-MRD) IN PATIENTS WITH MDS AND AML

EHA Library, Tamia Nguyen, 4209312

SAFETY OF EARLY G-CSF ADMINISTRATION DURING FIRST-CYCLE VENETOCLAX + AZACITIDINE IN AML: NO IMPACT ON SURVIVAL IN A REAL-WORLD EVIDENCE

EHA Library, Lubomir Minarik, 4209313

AMONG S-AML PATIENTS RECEIVING CPX-351 WITHOUT HSCT CONSOLIDATION, IDH2 BUT NOT IDH1 MUTATIONS  ARE RELATED WITH A LONGER SURVIVAL

EHA Library, Carola Riva, 4209314

SEX-STRATIFIED SINGLE-YEAR AML INCIDENCE: PERSISTENT MALE PREDOMINANCE AND FASTER ELDERLY RISE – SEER 2000–2022

EHA Library, Tapan Giri, 4209315

EARLY LOW-LEVEL PERIPHERAL BLOOD WT1 AT DAY +30 IDENTIFIES RELAPSE RISK AFTER ALLOGENEIC TRANSPLANTATION IN AML: A PROSPECTIVE MULTICENTER STUDY

EHA Library, Viktor Blaslov, 4209316

REGISTRATIONAL PHASE 3 STUDIES OF ZIFTOMENIB IN COMBINATION WITH NONINTENSIVE OR INTENSIVE CHEMOTHERAPY FOR NEWLY DIAGNOSED NPM1‑M OR KMT2A-R ACUTE MYELOID LEUKEMIA (AML): THE KOMET-017 TRIAL

EHA Library, Amer M. Zeidan, 4209317

HAS BONE MARROW CORE BIOPSY A CRUCIAL ROLE AT DIAGNOSIS AND AT POST-INDUCTION EVALUATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX?

EHA Library, Gianluca Martini, 4209318

QUATRO-APL: A PIVOTAL OPEN-LABEL PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF QTX-2101 IN COMBINATION WITH ALL-TRANS RETINOIC ACID IN NEWLY DIAGNOSED, LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA

EHA Library, Pau Montesinos, 4209320

CLOSING THE GAPS FOR PERSONALISED THERAPY IN NEWLY DIAGNOSED AML: IMPACT OF A MICRO-LEARNING ONLINE EDUCATION INITIATIVE ON THE PRACTICALITIES OF CARE

EHA Library, Ben Johnson, 4209321

PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE BY FLOW CYTOMETRY BEFORE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTSWITH AML OR MDS

EHA Library, huijuan Tian, 4209322

FRAILTY RISK ASSESSMENT IN OLDER PATIENTS WITH AML TREATED WITH VEN-AZA REGIMEN. SINGLE-CENTER EXPERIENCE.

EHA Library, Justyna Rybka, 4209323

REFINING RELAPSE RISK IN NON-TRANSPLANTED AML IN FIRST REMISSION: SURVIVAL BENCHMARKS AND THE IMPACT OF RUNX1 MUTATION

EHA Library, Eitan Kugler, 4209324

REAL-WORLD EFFICACY AND MOLECULAR RESPONSE ANALYSIS OF IVOSIDENIB-BASED REGIMENS VERSUS VENETOCLAX PLUS AZACITIDINE IN IDH1-MUTATED AML

EHA Library, Qingli Ji, 4209325

VENETOCLAX-BASED LOW-INTENSITY COMBINATIONS BEYOND FIRST LINE IN AML: REAL-WORLD OUTCOMES FROM THE MULTICENTER VENERA COHORT

EHA Library, Maksim Granatkin, 4209326

AGE-ASSOCIATED DIFFERENCES IN PREDICTORS OF SURVIVAL AND EARLY MORTALITY IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS

EHA Library, Evgenii Kunevich, 4209327

VENERA. A MULTICENTER EXPERIENCE OF LOW-INTENSITY TREATMENT BASED ON VENETOCLAX IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Nikita Pastukhov, 4209328

DOES MODERATE CYP3A4 INHIBITION REQUIRE VENETOCLAX DOSE REDUCTION IN ACUTE MYELOID LEUKEMIA? REAL-WORLD EVIDENCE WITH ISAVUCONAZOLE.

EHA Library, María Ibáñez Lacalle, 4209329

REMAIN-CR STUDY : REMISSION MAINTENANCE WITH ORAL AZACITIDINE IN AML PATIENTS IN COMPLETE RESPONSE AFTER VENETOCLAX + AZACITIDINE IN FIRST LINE

EHA Library, Helene Gardeney, 4209330

GENOMIC DNA-BASED QUANTITATIVE PCR IS A USEFUL METHOD FOR MRD ASSESSMENT IN NPM1-MUTATED AML

EHA Library, Pia-Sofia Ettala, 4209332

THIS REPORT PROVIDES A COMPREHENSIVE ASSESSMENT OF THE BASELINE CHARACTERISTICS, THERAPEUTIC PATTERNS, EFFICACY, AND TOLERABILITY OF ORAL-AZA IN THE POLISH POPULATION WITH AML.

EHA Library, Łukasz Bołkun, 4209333

ANALYSIS OF CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS FOR INFANT ACUTE MYELOID LEUKEMIA

EHA Library, Shaoyan Hu, 4209334

«AZACITIDINE+VENETOCLAX» IN REFRACTORY AML: REAL-WORLD DATA FROM UKRAINE DURING WAR

EHA Library, Bohdana Kuiavovych, 4209335

CARDIAC SAFETY OF L-ANNAMYCIN ACROSS HIGH CUMULATIVE ANTHRACYCLINE EXPOSURE: IMPLICATIONS FOR RELAPSED/REFRACTORY AML

EHA Library, Angela Dewar, 4209336

TWENTY YEARS OF EXPERIENCE WITH THE MRC-10 PROTOCOL FOR THE TREATMENT OF ADULT ACUTE MYELOID LEUKEMIA IN THE SOUTH OF TUNISIA

EHA Library, Nour Siala, 4209337

CLINICOPATHOLOGIC AND CYTOGENETIC CHARACTERISTICS, PROGNOSTIC PREDICTORS IN T-MN PATIENTS: A SINGLE-CENTER RETROSPECTIVE ANALYSIS

EHA Library, Huawei Jiang, 4209338

GENOMIC LANDSCAPE OF AML PATIENTS IN UKRAINE

EHA Library, Nataliia Levkovych, 4209339

TREATMENT OUTCOMES AND PROGNOSTIC FACTORS OF PAEDIATRIC ACUTE MYELOID LEUKAEMIA: A SINGLE-CENTER STUDY FORM A MIDDLE-INCOME COUNTRY

EHA Library, Hanen Charfi, 4209340

COMPARATIVE ANALYSIS OF T-CELL AND BONE MARROW CHIMERISM FOR RELAPSE PREDICTION IN ACUTE LEUKAEMIA POST-TRANSPLANTATION

EHA Library, Liting Chen, 4209341

PHASE 1/1B TRIAL OF IMETELSTAT AND AZACITIDINE WITH OR WITHOUT VENETOCLAX RELAPSED ACUTE MYELOID LEUKEMIA (IMAGINE TRIAL)

EHA Library, Douglas Tremblay, 4209342

POST-TRANSPLANTATION CYCLOPHOSPHAMIDE-BASED GRAFT VERSUS HOST DISEASE PROPHYLAXIS FOR MATCHED SIBLING DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA

EHA Library, Malek Benakli, 4209343

THERAPEUTIC EFFICACY ANALYSIS OF NEWLY DIAGNOSEDACUTE MYELOID LEUKEMIA(AML) BASED ON MINIMAL RESIDUAL DISEASE

EHA Library, Ye Hui Tan, 4209344

REAL-WORLD EARLY MORTALITY WITH CPX-351: AN INSTITUTIONAL EXPERIENCE COMPARED WITH PUBLISHED OUTCOMES

EHA Library, Sheenam Sheenam, 4209345

DELPHI CONSENSUS ON OPTIMAL TREATMENT STRATEGIES USING IDH1 INHIBITORS IN PATIENTS WITH R/R MIDH1 AML

EHA Library, Jorge Cortes, 4209346

REVUMENIB + VENETOCLAX/AZACITIDINE IN ADULTS WITH NEWLY DIAGNOSED NPM1M OR KMT2AR ACUTE LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002): TRIAL IN PROGRESS

EHA Library, Gerwin Huls, 4209347

MUTATIONAL LANDSCAPE AND SURVIVAL OUTCOMES OF ACUTE MYELOID LEUKEMIA IN CENTRAL KAZAKHSTAN: A REAL-WORLD ANALYSIS

EHA Library, Maxim Selivanov, 4209348

IMMUNOPHENOTYPE, CYTOGENETICS, AND MOLECULAR GENETICS OF ACUTE LEUKAEMIAS IN LAGOS, NIGERIA

EHA Library, Oluwafemi Akinwunmi, 4209349

AGE-DEPENDENT SURVIVAL DISPARITIES BETWEEN PUBLIC AND PRIVATE HEALTHCARE SETTINGS IN FLT3-ITD AML: DATA FROM THE BRAZILIAN AML REGISTRY

EHA Library, Luiza Perruso, 4209350

EFFICACY AND SAFETY OF LIPOSOMAL MITOXANTRONE COMBINED WITH VENETOCLAX, AZACITIDINE, AND CHIDAMIDE (VACM) IN ACUTE MONOCYTIC LEUKEMIA

EHA Library, Dairong Xie, 4209351

VALIDATING PIVOTAL TRIAL OUTCOMES: SINGLE-CENTER EXPERIENCE SHOWING MRD-NEGATIVITY AS THE PRIMARY DRIVER OF LONG-TERM OUTCOMES IN HIGH-RISK AML TREATED WITH CPX-351

EHA Library, ALBA MANASA GONZALEZ ARIAS, 4209352

EFFICACY OF LIPOSOMAL MITOXANTRONE COMBINED WITH VENETOCLAX AND AZACITIDINE FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Ye Hui Tan, 4209353

REDUCED-DOSE VENETOCLAX WITH POSACONAZOLE SHOWS COMPARABLE EFFICACY TO STANDARD-DOSE IN FIRST-LINE TREATMENT OF ACUTE MYELOID LEUKEMIA

EHA Library, Sang-A Kim, 4209354

VALIDATION OF THE ELN RISK CLASSIFICATIONS FOR AML IN A 971 PATIENTS UNICENTRIC COHORT

EHA Library, Diana Tholen, 4209355

LONG-COURSE (≥4 CYCLES) VENETOCLAX-AZACITIDINE IMPROVES OUTCOMES IN RAS-MUTATED AML: A REAL-WORLD STUDY

EHA Library, Tingjun Zhu, 4209356

PHASE 1, OPEN-LABEL, MULTI-CENTER TRIAL OF RPT1G IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES/NEOPLASMS

EHA Library, Dennise De Jesus Diaz, 4209357

TRANSCRIPTOMICS-BASED MULTI-OMICS APPROACH FOR IMPROVED RISK STRATIFICATION IN ACUTE MYELOID LEUKEMIA

EHA Library, yang yang, 4209358

PRE-INDUCTION WITH AZACITIDINE AND VENETOCLAX IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML): TWO YEARS SURVIVAL UPDATE OF A COMPARATIVE STUDY

EHA Library, Maher Salamoon, 4209359

REAL-WORLD OUTCOMES OF ACUTE MYELOID LEUKEMIA IN PATIENTS AGED ≥60 YEARS TREATED SINCE 2015: COHORT COMPARISON INCLUDING VENETOCLAX-BASED LESS-INTENSITY THERAPY

EHA Library, Alexander Wild, 4209360

REAL-WORLD OUTCOMES OF ACUTE MYELOID LEUKEMIA IN A RESOURCE-LIMITED, CONFLICT-AFFECTED SETTING: A SINGLE-CENTER COHORT FROM SYRIA

EHA Library, Mahmoud Alhamadeh Alswij, 4209361

ANALYSIS OF CLINICAL FEATURES AND RISK FACTORS OF NEUROLOGICAL COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Yajun Shi, 4209362

GENOMIC AND CLINICAL DETERMINANTS OF OUTCOME IN IRISH AML: A REAL-WORLD ANALYSIS  (2007–2025), SINGLE CENTRE EXPERIENCE.

EHA Library, Ezzat El Hassadi, 4209363

VENETOCLAX PLUS AZACITIDINE AND LENALIDOMIDE (AVL) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA/MYELODYSPLASTIC SYNDROMES: A SINGLE-CENTER, PROSPECTIVE, SINGLE-ARM CLINICAL STUDY

EHA Library, Dongfeng Zeng, 4209364

OUTCOMES IN YOUNG PATIENTS WITH ACUTE MYELOID LEUKEMIA: REAL-WORLD PRACTICE

EHA Library, Victor Solovyov, 4209365

EARLY PERIPHERAL BLAST CLEARANCE AS A PREDICTOR OF COMPLETE REMISSION AND OVERALL SURVIVAL

EHA Library, Chihaoui N, 4209366

OBSERVATIONAL STUDY OF ACUTE LEUKEMIA CASES TRANSFERRED FROM GUADELOUPE TO MAINLAND FRANCE

EHA Library, Louis GUÉZET, 4209367

EVALUATION OF THE RELATIONSHIP BETWEEN CYTOGENETIC / MOLECULAR RISK FACTORS AND TREATMENT RESPONSE, DISEASE COURSE AND SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Pınar Tığlıoğlu, 4209368

A NOVEL RISK STRATIFICATION MODEL FOR ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX PLUS HYPOMETHYLATIC AGENTS: A MULTICENTER RETROSPECTIVE STUDY

EHA Library, Sang-A Kim, 4209369

CLINICAL CHARACTERISTICS AND THERAPEUTIC OUTCOMES OF ASYMPTOMATIC NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Chunyan Chen, 4209370

OPTIMIZING MAINTENANCE STRATEGIES FOR UNFIT OR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA: INSIGHTS FROM A META-ANALYSIS AND A RETROSPECTIVE STUDY OF VENETOCLAX PLUS AZACITIDINE

EHA Library, weiguang cui, 4209371

A PHASE 3 STUDY OF REVUMENIB IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED NPM1-MUTATED ACUTE MYELOID LEUKEMIA (REVEAL-ND NPM1): TRIAL IN PROGRESS

EHA Library, Eytan Stein, 4209372

PROGNOSTIC IMPACT OF MOLECULAR-GENETIC RISK, COMORBIDITY BURDEN, AND ECOG PERFORMANCE STATUS IN ACUTE MYELOID LEUKEMIA: A PROSPECTIVE SINGLE-CENTER STUDY

EHA Library, Kateryna Khurdepa, 4209373

BLASTOID PLASMACYTOID DENDRITIC CELL NEOPLASM – 15 YEAR UNICENTER EXPERIENCE IN BULGARIA

EHA Library, Yanitsa Davidkova, 4209374

THERAPY-RELATED AML: DISTINCT GENETIC PROFILE AND INFERIOR OUTCOMES COMPARED WITH DE NOVO AML

EHA Library, Ajda Gunes, 4209375

ACUTE MYELOID LEUKEMIA REAL DATA OVER 5 YEARS IN ALBANIA (2020-2024)

EHA Library, Ana Qose, 4209376

FIVE-YEAR RETROSPECTIVE ANALYSIS OF ACUTE LEUKEMIA MORTALITY IN ARMENIA

EHA Library, Lusine Harutyunyan, 4209377

REAL-WORLD OUTCOMES OF VENETOCLAX PLUS CHEMOTHERAPY AS SALVAGE BRIDGE TO ALLOGENEIC STEM CELL TRANSPLANTATION IN RELAPSED / REFRACTORY ACUTE MYELOID LEUKEMIA: A MULTICENTER PERUVIAN COHORT

EHA Library, Cesar Samanez, 4209378

VALIDATION AND COMPARISON OF ELN 2024 REVISED AND MAYO GENETIC RISK MODELS IN PATIENTS WITH AML RECEIVING VENETOCLAX-AZACITIDINE：A REAL-WORLD STUDY FROM CHINA

EHA Library, weiguang cui, 4209379

CLINICAL AND BIOLOGICAL CHARACTERISTICS OF ACUTE MYELOID LEUKEMIA IN PATIENTS FROM THE LENINGRAD REGION AND SAINT PETERSBURG

EHA Library, Sergey Voloshin, 4209380

NEUTROPENIC ENTEROCOLITIS IN ADULT PATIENTS DIAGNOSED WITH ACUTE LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY IN A SINGLE CENTER: DESCRIPTION OF CLINICAL CHARACTERISTICS AND MANAGEMENT RESULTS.

EHA Library, Monica Alejandra Romero Riquelme, 4209381

HYDROCARBON EXPOSURE AND THE RISK OF MYELOID MALIGNANCIES: A SYSTEMATIC REVIEW WITH TRANSLATIONAL IMPLICATIONS FOR OIL PRODUCING REGIONS, INCLUDING RIAU, INDONESIA

EHA Library, Nanda Noor Muhammad Nasution, 4209382

THE PROGNOSTIC EFFECT OF BONE MARROW FIBROSIS AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS ASSESSED WITH OTHER LABORATORY PARAMETERS: SINGLE CENTER DATA

EHA Library, Mehmet Yilmaz, 4209383

NEXT GENERATION SEQUENCING, CLASSICAL CYTOGENETICS AND MOLECULAR TECHNIQUES AS COMPLEMENTARY TOOLS IN THE CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA (AML): A REAL-WORLD ANALYSIS IN LATIN AMERICA

EHA Library, Cecilia Lang, 4209384

RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOME  OF AUTOLOGOUS SCT IN ACUTE MYELOID LEUKAEMIA PATIENTS IN CR1 VERSUS  AML IN CR1 WITHOUT AUTOSCT ACROSS ALL RISK GROUPS,  A SINGLE CENTRE EXPERIENCE.

EHA Library, Adilah ZAKI MORAD, 4209385

REGULATORY DIVERGENCE IN R/R AML: CONTRASTING FDA AND EMA APPROACHES TO REAL-WORLD EVIDENCE AND TRIAL DESIGN

EHA Library, Sinan Bardakci Sarac, 4209386

AZA-VEN-GILTERITINIB COMBINATION AS SALVAGE THERAPY IN RELAPSED AND REFRACTORY FLT3-ITD MUTANT AML: SINGLE-CENTRE REAL-WORLD DATA

EHA Library, Denis Cetin, 4209387

SEASONAL DISTRIBUTION OF ACUTE PROMYELOCYTIC LEUKAEMIA IN TÜRKİYE

EHA Library, Ali Turunç, 4209388

TRIPLE THERAPY WITH AZACITIDINE, VENETOCLAX AND GILTERITINIB AS A THERAPEUTIC OPTION FOR ADULTS PATIENTS WITH REFRACTORY/RELAPSED FLT3 MUTATED ACUTE MYELOID LEUKEMIA – A SINGLE CENTER EXPERIENCE

EHA Library, Bianca Constantin, 4209389

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES IN SECONDARY ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS

EHA Library, Melis Bektaş, 4209390

COMPLETE REMISSION AND IMPROVED SURVIVAL OF PATIENTS WITH NUP214 FUSION GENES TREATED WITH VENETOCLAX-BASED CHEMOTHERAPY

EHA Library, Liya Ma, 4209391

THE OUTCOME OF A SUBSIDIZED COMPREHENSIVE FINANCIAL PACKAGE FOR THE TREATMENT OF AML IN THE ABSENCE OF UNIVERSAL HEALTH CARE IN THE LOW AND MIDDLE INCOME SETTING

EHA Library, Anne Mwirigi, 4209392

FACTORS ASSOCIATED WITH EARLY MORTALITY DURING INTENSIVE INDUCTION CHEMOTHERAPY IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Chihaoui N, 4209393

FRONTLINE AZACITIDINE–VENETOCLAX IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: REAL-WORLD DATA FROM A SINGLE TERTIARY CARE CENTRE IN INDIA

EHA Library, Chaitanya H Balakrishnan, 4209394

REAL-WORLD OUTCOMES OF HYPOMETHYLATING AGENTS AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA: A MONOCENTRIC EXPERIENCE.

EHA Library, Luana Fianchi, 4209395

CLINICAL IMPACT OF NEXT-GENERATION SEQUENCING ON RE-CLASSIFICATION AND POST-REMISSION TREATMENT STRATEGY IN ACUTE MYELOID LEUKEMIA – A SINGLE CENTER STUDY

EHA Library, Mirjana Cucakovic, 4209396

IVORY-MAST: STUDY DESIGN OF A PHASE 2 TRIAL EVALUATING IVOSIDENIB AS MAINTENANCE THERAPY IN IDH1-MUTATED AML OR HIGH-RISK MDS INELIGIBLE FOR TRANSPLANT

EHA Library, Ying Wang, 4209397

ACUTE MYELOID LEUKEMIA ASSOCIATED WITH BARDET-BIEDL SYNDROME:A CASE REPORT

EHA Library, Belgacem Raoudha, 4209398

PREDICTIVE VALUE OF THE NEUTROPHIL-TO-LYMPHOCYTE RATIO FOR 30-DAY MORTALITY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Andreea Vasile, 4209399

SUSPECTED TRANSIENT HEPATOSPLENIC PELIOSIS IN AML-M2 AFTER INDUCTION  COMPLICATED BY SEVERE SARS-COV-2 INFECTION: « CASE REPORT »

EHA Library, Rihab BENTAHAR, 4209400

BLUEBERRY MUFFIN RASH AS THE INITIAL PRESENTATION OF CONGENITAL ACUTE MYELOID LEUKEMIA: DIAGNOSTIC PATHWAYS IN TWO INFANTS WITH KMT2A-REARRANGED AML

EHA Library, Athanasios Tragiannidis, 4209401

EFFICACY AND SAFETY OF IVOSIDENIB-BASED THERAPY IN IDH1-MUTATED ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER REAL-WORLD STUDY

EHA Library, Guopan Yu, 4209402

IVOSIDENIB AS LONG-TERM MAINTENANCE TREATMENT FOR PATIENTS WITH IDH1-MUTATED ACUTE MYELOID LEUKEMIA (AML): A RETROSPECTIVE CASE SERIES

EHA Library, Ligen Liu, 4209403

MULTI-MODULE TARGETED NURSING PRACTICE AND OUTCOME ANALYSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH PRE-EXISTING INTESTINAL INFECTIONS UNDERGOING DONOR-DERIVED CD33 CAR-T THERAPY

EHA Library, Xiaoyuan Wu, 4209404

IS EXRAMEDULLARY INVOLVEMENT A DISTINICT ENTITY IN NPM1-MUTATED AML WITH NORMAL CYTOGENETICS ?A CASE REPORT AND LITERATURE REVIEW

EHA Library, Hassan Sibai, 4209405

PREDICTORS OF REDUCED RELAPSE-FREE SURVIVAL IN YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Chihaoui N, 4209406

POST-INDUCTION FAILURE IN ADULT ACUTE MYELOID LEUKEMIA: TOWARD PREDICTIVE STRATIFICATION OF HIGH-RISK PATIENTS

EHA Library, Ahlem Slama, 4209407

CONCURRENT LANGERHANS CELL HISTIOCYTOSIS AND KMT2A-REARRANGED ACUTE MYELOID LEUKEMIA SHOWING DUAL RESPONSE TO AZACITIDINE

EHA Library, Derya Demirtas, 4209408

PRIMARY ISOLATED MYELOID SARCOMA WITHOUT MARROW INVOLVEMENT: PARTIAL RESPONSE TO 7+3 FOLLOWED BY FURTHER RADIOLOGIC REGRESSION ON VENETOCLAX IN A NON-ELIGIBLE PATIENT

EHA Library, Anna Sergeieva, 4209409

PATIENT OUTCOMES FOR ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROMES WITH MUTATED TP53 AT CORK UNIVERSITY HOSPITAL, IRELAND

EHA Library, David Parfrey, 4209410

REAL-WORLD PRACTICE WITH GENERIC VENETOCLAX AND GENERIC HYPOMETHYLATING (HMA) AGENTS IN NEWLY DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA (AML) WITH DIFFERENT RISK GROUPS: A STUDY ON A SYRIAN COHORT

EHA Library, Maher Salamoon, 4209411

A CLINICAL CASE OF AML WITH FLT3-ITD FRAMESHIFT MUTATION

EHA Library, Tatiana Subbotina, 4209412

TARGETED THERAPIES MODULATE ANTIFUNGAL HOST DEFENSE IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Vasileios Oikonomou, 4209413